http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102122802-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 |
| filingDate | 2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102122802-B1 |
| titleOfInvention | Vaccine for treating and preventing tuberculosis comprising B cell loading α-galactosylceramide and ESAT6 |
| abstract | The present invention relates to a cell vaccine mediated by B cells loaded with ligands and antigens of natural killer T cells. Specifically, the present invention relates to a cell vaccine having excellent anti-tuberculosis effect by using alpha-galactosylceramide (αGC) as a ligand of natural killer T cells and using ESAT6 as an antigen. The present invention maximizes antigen delivery by targeting ESAT6 among the antigens of tuberculosis and expressing them in Vaccinia virus, and transducing them into B cells, thereby loading alpha-galactosyl ceramide, a ligand of natural killer T cells, It provides a cell-based vaccine that has an immune response-inducing effect and a CFU-reducing effect on infection. |
| priorityDate | 2018-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 224.